For 26 days, study participants throughout 10 countries either received J&J’s drug candidate, JNJ-1802, or placebo doses daily. The phase 2 study found the therapy, which is designed to target circulating dengue serotypes, reduced antiviral activity and was safe and effective, according to a news release.
About 4 billion people worldwide live in areas at risk for dengue, according to the CDC. There’s a dengue vaccine available, but no antivirals for the virus are approved. J&J did not disclose when it might submit its experimental drug for regulatory approval.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
